To investigate if the market capsule and the phase III capsule of 20 mg H 199/18 are bioequivalent following single dose administration under fasting conditions.

Study identifier:SH-QBE-0057

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

To investigate if the market capsule and the phase III capsule of 20 mg H 199/18 are bioequivalent following single dose administration under fasting conditions.

Medical condition

gastrointestinal diseases

Phase

N/A

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Jan 1971
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria